{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:45:48Z","timestamp":1788363948805,"version":"build-2803163510"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T00:00:00Z","timestamp":1709856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Testosterone therapy (TTh) has been shown to improve libido in women with sexual dysfunction, but its utilization has been limited due to concern for cardiovascular events and past studies reporting highly variable results.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>To assess the association of TTh in women with major adverse cardiac events (MACEs), including heart attack, stroke, or death, using a large database.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The TriNetX Diamond Network was queried from 2009 to 2022. Our study cohort included adult females with \u22653 systemic testosterone prescriptions within a year. Our control cohort excluded females with any testosterone prescriptions, polycystic ovary syndrome, or androgen excess. Both cohorts excluded females with prior heart failure, unstable angina, intersex surgery (female to male), personal history of sex reassignment, or gender identity disorders. Propensity matching between the cohorts was performed. A subanalysis by age was conducted (18-55 and\u2009&amp;gt;55 years).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Outcomes<\/jats:title>\n                  <jats:p>We evaluated the association of TTh to the following: MACE, upper or lower emboli or deep vein thrombosis (DVT), pulmonary embolism (PE), breast neoplasm, and hirsutism within 3 years of TTh.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>When compared with propensity-matched controls, adult females with TTh had a lower risk of MACE (risk ratio [RR], 0.64; 95% CI, 0.51-0.81), DVT (RR, 0.61; 95% CI, 0.42-0.90), PE (RR, 0.48; 95% CI, 0.28-0.82), and malignant breast neoplasm (RR, 0.48; 95% CI, 0.37-0.62). Similarly, females aged 18 to 55 years with TTh had a lower risk of MACE (RR, 0.49; 95% CI, 0.28-0.85) and DVT (RR, 0.48; 95% CI, 0.25-0.93) and a similar risk of malignant breast neoplasm (RR, 0.62; 95% CI, 0.34-1.12). Females aged \u226556\u00a0years with TTh had a similar risk of MACE (RR, 0.84; 95% CI, 0.64-1.10), DVT (RR, 0.82; 95% CI, 0.50-1.36), and PE (RR, 0.52; 95% CI, 0.26-1.05) and a significantly lower risk of malignant breast neoplasm (RR, 0.51; 95% CI, 0.38-0.68). Risk of hirsutism was consistently higher in those with TTh as compared with propensity-matched controls.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Implications<\/jats:title>\n                  <jats:p>Our results contribute to safety data on TTh, a therapy for sexual dysfunction in women.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Strengths and Limitations<\/jats:title>\n                  <jats:p>The TriNetX Diamond Network allows for significant generalizability but has insufficient information for some factors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>We found a decreased risk of MACE among women with TTh as compared with matched controls and a similar risk of MACE in postmenopausal women while demonstrating a similar or significantly lower risk of breast cancer on age-based subanalysis.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jsxmed\/qdae032","type":"journal-article","created":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T04:49:55Z","timestamp":1709959795000},"page":"414-419","source":"Crossref","is-referenced-by-count":16,"title":["Testosterone therapy in females is not associated with increased cardiovascular or breast cancer risk: a claims database analysis"],"prefix":"10.1093","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9952-4888","authenticated-orcid":false,"given":"Pranjal","family":"Agrawal","sequence":"first","affiliation":[{"name":"School of Medicine, Johns Hopkins University , Baltimore, MD 21205 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajya M","family":"Singh","sequence":"additional","affiliation":[{"name":"School of Medicine, Johns Hopkins University , Baltimore, MD 21205 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Hsueh","sequence":"additional","affiliation":[{"name":"School of Medicine, Georgetown University , Washington, DC 20007 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurora","family":"Grutman","sequence":"additional","affiliation":[{"name":"School of Medicine, Johns Hopkins University , Baltimore, MD 21205 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5197-7426","authenticated-orcid":false,"given":"Clemens","family":"An","sequence":"additional","affiliation":[{"name":"Larner College of Medicine at the University of Vermont , Burlington, VT 05405 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey","family":"Able","sequence":"additional","affiliation":[{"name":"University of Texas Medical Branch at Galveston , Galveston, TX 77555 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Una","family":"Choi","sequence":"additional","affiliation":[{"name":"School of Medicine, Johns Hopkins University , Baltimore, MD 21205 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaden","family":"Kohn","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Johns Hopkins University , Baltimore, MD 21287 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Clifton","sequence":"additional","affiliation":[{"name":"The James Buchanan Brady Urological Institute, Johns Hopkins University , Baltimore, MD 21287 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor P","family":"Kohn","sequence":"additional","affiliation":[{"name":"The James Buchanan Brady Urological Institute, Johns Hopkins University , Baltimore, MD 21287 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,3,8]]},"reference":[{"issue":"7","key":"2024050206213220300_ref1","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41443-022-00613-0","article-title":"The clinical management of testosterone replacement therapy in postmenopausal women with hypoactive sexual desire disorder: a review","volume":"34","author":"Uloko","year":"2022","journal-title":"Int J Impot Res"},{"issue":"2","key":"2024050206213220300_ref2","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jsxm.2015.12.033","article-title":"Androgens and female sexual function and dysfunction\u2014findings from the Fourth International Consultation of Sexual Medicine","volume":"13","author":"Davis","year":"2016","journal-title":"J Sex Med"},{"issue":"5","key":"2024050206213220300_ref3","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jsxm.2020.10.009","article-title":"International Society for the Study of Women\u2019s sexual health clinical practice guideline for the use of systemic testosterone for hypoactive sexual desire disorder in women","volume":"18","author":"Parish","year":"2021","journal-title":"J Sex Med"},{"issue":"10","key":"2024050206213220300_ref4","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1210\/jc.2019-01603","article-title":"Global consensus position statement on the use of testosterone therapy for women","volume":"104","author":"Davis","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2024050206213220300_ref5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1089\/jwh.2018.7494","article-title":"Androgen therapy in women","volume":"29","author":"Vegunta","year":"2020","journal-title":"J Womens Health (Larchmt)"},{"issue":"1","key":"2024050206213220300_ref6","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.maturitas.2008.11.001","article-title":"Study of adverse outcomes in women using testosterone therapy","volume":"62","author":"van Staa","year":"2009","journal-title":"Maturitas"},{"issue":"9","key":"2024050206213220300_ref7","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.jsxm.2019.07.012","article-title":"Global consensus position statement on the use of testosterone therapy for women","volume":"16","author":"Davis","year":"2019","journal-title":"J Sex Med"},{"issue":"5","key":"2024050206213220300_ref8","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1080\/13697137.2019.1637079","article-title":"Global consensus position statement on the use of testosterone therapy for women","volume":"22","author":"Davis","year":"2019","journal-title":"Climacteric"},{"key":"2024050206213220300_ref9","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.maturitas.2019.07.001","article-title":"Global consensus position statement on the use of testosterone therapy for women","volume":"128","author":"Davis","year":"2019","journal-title":"Maturitas"},{"issue":"12","key":"2024050206213220300_ref10","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/S2213-8587(15)00284-3","article-title":"Testosterone in women\u2014the clinical significance","volume":"3","author":"Davis","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"2024050206213220300_ref11","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.euf.2022.10.008","article-title":"Management of erythrocytosis in men receiving testosterone therapy: clinical consultation guide","volume":"9","author":"Agrawal","year":"2023","journal-title":"Eur Urol Focus"},{"issue":"2","key":"2024050206213220300_ref12","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa2215025","article-title":"Cardiovascular safety of testosterone-replacement therapy","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"2024050206213220300_ref13","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women\u2019s Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"issue":"2","key":"2024050206213220300_ref14","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1161\/ATVBAHA.114.304821","article-title":"Extreme concentrations of endogenous sex hormones, ischemic heart disease, and death in women","volume":"35","author":"Benn","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"22","key":"2024050206213220300_ref15","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1016\/j.jacc.2018.01.083","article-title":"Endogenous sex hormones and incident cardiovascular disease in post-menopausal women","volume":"71","author":"Zhao","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2024050206213220300_ref16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jcct.2018.09.010","article-title":"Association of endogenous sex hormone levels with coronary artery calcium progression among post-menopausal women in the Multi-ethnic Study of Atherosclerosis (MESA)","volume":"13","author":"Subramanya","year":"2019","journal-title":"J Cardiovasc Comput Tomogr"},{"issue":"10","key":"2024050206213220300_ref17","doi-asserted-by":"crossref","first-page":"e3798","DOI":"10.1210\/clinem\/dgaa500","article-title":"Sex hormones and incident heart failure in men and postmenopausal women: the Atherosclerosis Risk in Communities study","volume":"105","author":"Zhao","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2024050206213220300_ref18","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1210\/jc.2017-02421","article-title":"High androgens in postmenopausal women and the risk for atherosclerosis and cardiovascular disease: the Rotterdam Study","volume":"103","author":"Meun","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"2024050206213220300_ref19","article-title":"Cardiovascular risk in menopausal women and our evolving understanding of menopausal hormone therapy: risks, benefits, and current guidelines for use","author":"Prabakaran","year":"30, 2021","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"16","key":"2024050206213220300_ref20","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.jacc.2010.03.090","article-title":"Testosterone therapy in women with chronic heart failure: a pilot double-blind, randomized, placebo-controlled study","volume":"56","author":"Iellamo","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"2024050206213220300_ref21","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1530\/EC-18-0480","article-title":"The association between serum testosterone and insulin resistance: a longitudinal study","volume":"7","author":"Ottarsdottir","year":"2018","journal-title":"Endocr Connect"},{"issue":"1","key":"2024050206213220300_ref22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/01.mca.0000236290.79306.d1","article-title":"Endogenous testosterone and endothelial function in postmenopausal women","volume":"18","author":"Montalcini","year":"2007","journal-title":"Coron Artery Dis"},{"issue":"2","key":"2024050206213220300_ref23","doi-asserted-by":"crossref","first-page":"120","DOI":"10.4103\/aja.aja_6_18","article-title":"Randomized controlled trials\u2014mechanistic studies of testosterone and the cardiovascular system","volume":"20","author":"Jones","year":"2018","journal-title":"Asian J Androl"},{"issue":"2","key":"2024050206213220300_ref24","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1677\/JOE-10-0057","article-title":"Sex hormone modulation of proinflammatory cytokine and C-reactive protein expression in macrophages from older men and postmenopausal women","volume":"206","author":"Corcoran","year":"2010","journal-title":"J Endocrinol"},{"issue":"1","key":"2024050206213220300_ref25","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41416-021-01392-z","article-title":"Endogenous hormones and risk of invasive breast cancer in pre- and post-menopausal women: findings from the UK Biobank","volume":"125","author":"Tin Tin","year":"2021","journal-title":"Br J Cancer"},{"issue":"1","key":"2024050206213220300_ref26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1001\/archinternmed.2008.507","article-title":"Influence of estrogen plus testosterone supplementation on breast cancer","volume":"169","author":"Ness","year":"2009","journal-title":"Arch Intern Med"},{"issue":"3","key":"2024050206213220300_ref27","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.maturitas.2015.06.002","article-title":"Testosterone and breast cancer prevention","volume":"82","author":"Glaser","year":"2015","journal-title":"Maturitas"},{"issue":"2","key":"2024050206213220300_ref28","doi-asserted-by":"crossref","first-page":"150","DOI":"10.4274\/ejbh.galenos.2021.6213","article-title":"Breast cancer incidence reduction in women treated with subcutaneous testosterone: testosterone therapy and breast cancer incidence study","volume":"17","author":"Donovitz","year":"2021","journal-title":"Eur J Breast Health"},{"issue":"7","key":"2024050206213220300_ref29","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/GME.0000000000000828","article-title":"Subcutaneous testosterone-letrozole therapy before and concurrent with neoadjuvant breast chemotherapy: clinical response and therapeutic implications","volume":"24","author":"Glaser","year":"2017","journal-title":"Menopause"},{"issue":"12","key":"2024050206213220300_ref30","doi-asserted-by":"crossref","first-page":"6615","DOI":"10.21873\/anticanres.13028","article-title":"Does transdermal testosterone increase the risk of developing breast cancer?","volume":"38","author":"Gera","year":"2018","journal-title":"Anticancer Res"},{"issue":"1","key":"2024050206213220300_ref31","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13058-020-01332-4","article-title":"Hormonal determinants of mammographic density and density change","volume":"22","author":"Gabrielson","year":"2020","journal-title":"Breast Cancer Res"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/21\/5\/414\/57359413\/qdae032.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/21\/5\/414\/57359413\/qdae032.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T06:22:08Z","timestamp":1714630928000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/21\/5\/414\/7624419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,8]]},"references-count":31,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,3,8]]},"published-print":{"date-parts":[[2024,4,30]]}},"URL":"https:\/\/doi.org\/10.1093\/jsxmed\/qdae032","relation":{},"ISSN":["1743-6095","1743-6109"],"issn-type":[{"value":"1743-6095","type":"print"},{"value":"1743-6109","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5]]},"published":{"date-parts":[[2024,3,8]]}}}